vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是GIBRALTAR INDUSTRIES, INC.的1.7倍（$373.9M vs $225.0M），GIBRALTAR INDUSTRIES, INC.同比增速更快（24.9% vs 20.9%），GIBRALTAR INDUSTRIES, INC.自由现金流更多（$26.2M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs -12.3%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
PAHC vs ROCK — 直观对比
营收规模更大
PAHC
是对方的1.7倍
$225.0M
营收增速更快
ROCK
高出4.0%
20.9%
自由现金流更多
ROCK
多$18.0M
$8.3M
两年增速更快
PAHC
近两年复合增速
-12.3%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $225.0M |
| 净利润 | $27.5M | — |
| 毛利率 | 35.5% | 25.3% |
| 营业利润率 | 13.5% | 7.9% |
| 净利率 | 7.3% | — |
| 营收同比 | 20.9% | 24.9% |
| 净利润同比 | 762.1% | — |
| 每股收益（稀释后） | $0.67 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAHCROCK
| Q4 25 | $373.9M | $225.0M | ||
| Q3 25 | $363.9M | $310.9M | ||
| Q2 25 | $378.7M | $309.5M | ||
| Q1 25 | $347.8M | $290.0M | ||
| Q4 24 | $309.3M | $180.1M | ||
| Q3 24 | $260.4M | $277.1M | ||
| Q2 24 | $273.2M | $273.6M | ||
| Q1 24 | $263.2M | $292.5M |
净利润PAHCROCK
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.5M | $-89.1M | ||
| Q2 25 | $17.2M | $26.0M | ||
| Q1 25 | $20.9M | $21.1M | ||
| Q4 24 | $3.2M | — | ||
| Q3 24 | $7.0M | $34.0M | ||
| Q2 24 | $752.0K | $32.2M | ||
| Q1 24 | $8.4M | $24.9M |
毛利率PAHCROCK
| Q4 25 | 35.5% | 25.3% | ||
| Q3 25 | 32.9% | 26.6% | ||
| Q2 25 | 29.0% | 28.4% | ||
| Q1 25 | 30.1% | 26.8% | ||
| Q4 24 | 32.9% | 29.0% | ||
| Q3 24 | 32.1% | 29.4% | ||
| Q2 24 | 31.9% | 30.5% | ||
| Q1 24 | 30.2% | 28.9% |
营业利润率PAHCROCK
| Q4 25 | 13.5% | 7.9% | ||
| Q3 25 | 14.1% | 12.8% | ||
| Q2 25 | 8.9% | 12.8% | ||
| Q1 25 | 9.6% | 8.8% | ||
| Q4 24 | 8.3% | 13.3% | ||
| Q3 24 | 6.8% | 15.6% | ||
| Q2 24 | 6.7% | 14.9% | ||
| Q1 24 | 7.6% | 10.8% |
净利率PAHCROCK
| Q4 25 | 7.3% | — | ||
| Q3 25 | 7.3% | -28.6% | ||
| Q2 25 | 4.5% | 8.4% | ||
| Q1 25 | 6.0% | 7.3% | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 2.7% | 12.3% | ||
| Q2 24 | 0.3% | 11.8% | ||
| Q1 24 | 3.2% | 8.5% |
每股收益（稀释后）PAHCROCK
| Q4 25 | $0.67 | — | ||
| Q3 25 | $0.65 | $-2.98 | ||
| Q2 25 | $0.43 | $0.87 | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.08 | — | ||
| Q3 24 | $0.17 | $1.11 | ||
| Q2 24 | $0.02 | $1.05 | ||
| Q1 24 | $0.21 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | $115.7M |
| 总债务越低越好 | $624.2M | $0 |
| 股东权益账面价值 | $332.4M | $950.4M |
| 总资产 | $1.4B | $1.4B |
| 负债/权益比越低杠杆越低 | 1.88× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资PAHCROCK
| Q4 25 | $74.5M | $115.7M | ||
| Q3 25 | $85.3M | $89.4M | ||
| Q2 25 | $77.0M | $43.3M | ||
| Q1 25 | $70.4M | $25.1M | ||
| Q4 24 | $67.1M | $269.5M | ||
| Q3 24 | $89.8M | $228.9M | ||
| Q2 24 | $114.6M | $179.1M | ||
| Q1 24 | $98.7M | $146.7M |
总债务PAHCROCK
| Q4 25 | $624.2M | $0 | ||
| Q3 25 | $628.0M | $0 | ||
| Q2 25 | $631.7M | $0 | ||
| Q1 25 | $635.4M | $0 | ||
| Q4 24 | $639.1M | $0 | ||
| Q3 24 | $295.2M | $0 | ||
| Q2 24 | $312.1M | $0 | ||
| Q1 24 | — | $0 |
股东权益PAHCROCK
| Q4 25 | $332.4M | $950.4M | ||
| Q3 25 | $311.7M | $951.8M | ||
| Q2 25 | $285.7M | $1.0B | ||
| Q1 25 | $266.0M | $1.0B | ||
| Q4 24 | $246.8M | $1.0B | ||
| Q3 24 | $258.5M | $1.0B | ||
| Q2 24 | $256.6M | $975.7M | ||
| Q1 24 | $270.1M | $940.2M |
总资产PAHCROCK
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $966.3M | $1.4B | ||
| Q2 24 | $982.2M | $1.4B | ||
| Q1 24 | $979.0M | $1.3B |
负债/权益比PAHCROCK
| Q4 25 | 1.88× | 0.00× | ||
| Q3 25 | 2.01× | 0.00× | ||
| Q2 25 | 2.21× | 0.00× | ||
| Q1 25 | 2.39× | 0.00× | ||
| Q4 24 | 2.59× | 0.00× | ||
| Q3 24 | 1.14× | 0.00× | ||
| Q2 24 | 1.22× | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $35.5M |
| 自由现金流经营现金流 - 资本支出 | $8.3M | $26.2M |
| 自由现金流率自由现金流/营收 | 2.2% | 11.7% |
| 资本支出强度资本支出/营收 | 3.0% | 4.1% |
| 现金转化率经营现金流/净利润 | 0.70× | — |
| 过去12个月自由现金流最近4个季度 | $47.3M | $120.6M |
8季度趋势，按日历期对齐
经营现金流PAHCROCK
| Q4 25 | $19.4M | $35.5M | ||
| Q3 25 | $9.3M | $73.0M | ||
| Q2 25 | $21.3M | $44.9M | ||
| Q1 25 | $43.2M | $13.7M | ||
| Q4 24 | $3.1M | $19.9M | ||
| Q3 24 | $12.6M | $64.7M | ||
| Q2 24 | $28.4M | $36.5M | ||
| Q1 24 | $11.4M | $53.2M |
自由现金流PAHCROCK
| Q4 25 | $8.3M | $26.2M | ||
| Q3 25 | $-4.5M | $64.8M | ||
| Q2 25 | $8.1M | $27.3M | ||
| Q1 25 | $35.4M | $2.3M | ||
| Q4 24 | $-4.7M | $14.1M | ||
| Q3 24 | $3.0M | $60.5M | ||
| Q2 24 | $15.4M | $33.5M | ||
| Q1 24 | $1.7M | $48.8M |
自由现金流率PAHCROCK
| Q4 25 | 2.2% | 11.7% | ||
| Q3 25 | -1.2% | 20.8% | ||
| Q2 25 | 2.1% | 8.8% | ||
| Q1 25 | 10.2% | 0.8% | ||
| Q4 24 | -1.5% | 7.8% | ||
| Q3 24 | 1.2% | 21.8% | ||
| Q2 24 | 5.6% | 12.2% | ||
| Q1 24 | 0.6% | 16.7% |
资本支出强度PAHCROCK
| Q4 25 | 3.0% | 4.1% | ||
| Q3 25 | 3.8% | 2.6% | ||
| Q2 25 | 3.5% | 5.7% | ||
| Q1 25 | 2.2% | 3.9% | ||
| Q4 24 | 2.5% | 3.3% | ||
| Q3 24 | 3.7% | 1.5% | ||
| Q2 24 | 4.8% | 1.1% | ||
| Q1 24 | 3.7% | 1.5% |
现金转化率PAHCROCK
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 1.24× | 1.73× | ||
| Q1 25 | 2.07× | 0.65× | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.81× | 1.90× | ||
| Q2 24 | 37.80× | 1.13× | ||
| Q1 24 | 1.36× | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
